metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population
versus placebo
	durvalumab alone vs. placebo	1	-1050 [-1822; -278] /10000 183/476 vs. 116/237	-2129 [-2878; -1379] /10000 214/476 vs. 157/237	-